



Anti-hyperglycemic, Anti-hyperlipidemic, Anti-inflammatory, and Antioxidant Efficacy of *Ferula assa-foetida* in Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, and Placebo-Controlled Trial

Sahar Golabi ¹, Maryam Adelipour ², Mahsa Naghashpour ³, Abdollah Khanzadeh ⁴, Naser Kamyari ⁵, Mahshid Naghashpour ^{6,*}

¹ Department of Medical Physiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran

² Department of Biochemistry, School of Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³ Department of Anatomical Sciences, School of Medicine, Arak University of Medical Sciences, Arak, Iran

⁴ Department of Clinical Medical Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran

⁵ Abadan University of Medical Sciences, Abadan, Iran

⁶ Department of Nutrition, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran

*Corresponding Author: Department of Nutrition, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran. Email: m.naghashpour@abadanums.ac.ir

Received: 3 January, 2024; Revised: 10 May, 2025; Accepted: 15 July, 2025

Abstract

Background: Despite the accessibility of synthetic antidiabetic drugs for the management of type 2 diabetes mellitus (T2DM), their side effects and cost have drawn significant attention to novel natural alternatives for treatment.

Objectives: The present study evaluated the effectiveness of *Ferula assa-foetida* as a potential therapeutic agent against T2DM.

Methods: A double-blind, randomized controlled clinical trial was conducted at Ayatollah Taleghani Medical and Educational Center, Abadan University of Medical Sciences, Abadan, Iran. A simple randomization method using a table of random numbers to create a random sequence was applied, and allocation concealment was performed sequentially using numbered, sealed, and opaque envelopes to hide random allocation. Patients received capsules (250 mg × 2/day) of either starch (placebo, n = 10) or *F. assa-foetida* (*assa-foetida*, n = 10) for 90 days. Biochemical parameters, physical activity (PA), and diet were evaluated at baseline and the end of the study.

Results: Oral administration of *F. assa-foetida* for 90 days showed an increase in the median and IQR of ESR [10.5 (11.3) mm/h at baseline and 12 (8) mm/h on day 90, within group mean difference: -4.8 mm/h, 95% CI: -8.7, -0.84; P = 0.017] and a reduction in HDL-C [40 ± 10.03 mg/dL at baseline and 32.3 ± 6.9 mg/dL on day 90, within group mean difference: 7.7 mg/dL, 95% CI: 0.2, 14.2; P = 0.046] was found in the *assa-foetida* group. Patients in the *assa-foetida*-treated group showed a higher value of serum glutamic pyruvic transaminase (SGPT) compared with the placebo on day 90 [25 (12) vs. 16.5 (7.5), respectively, between group mean difference: -7.71 IU/L, 95% CI: -13.92, -1.49; P = 0.036]. The *assa-foetida*-treated group consumed fewer snacks and desserts [48 (6) vs. 57 (14), between group mean difference: 9.1, 95% CI: 1.7, 16.6; P = 0.021] on day 90 compared to the placebo, more from whole grains [23 (3) vs. 11 (5), within group mean difference: 12.9, 95% CI: 7.1, 18.6; P = 0.018], refined grains [20.5 (6) vs. 16 (9.25), within group mean difference: -7, 95% CI: -13.3, -0.7; P = 0.034], and potatoes [6 (4) vs. 2 (3.75), within group mean difference: -4, 95% CI: -7.2, -0.8; P = 0.028], and less from nuts and seeds [19 (2.5) vs. 22.5 (6.5), within group mean difference: 2.2, 95% CI: 0.2, 4.2; P = 0.041] on day 90 compared to baseline. At the same time, the patients in the placebo group consumed more refined grains [22 (5.5) vs. 15 (4.25), within group mean difference: -6.3, 95% CI: -10.6, -2.1; P = 0.012] and legumes [20 (5.25) vs. 14.5 (2.5), within group mean difference: -4.7, 95% CI: -8.8, -0.49; P = 0.035].

Conclusions: Taking the *assa-foetida* supplement alone without following positive changes in dietary intake is insufficient to demonstrate the anti-hyperglycemic, anti-inflammatory, and antioxidant efficacy of *F. assa-foetida* in patients with T2DM.

Keywords: *Ferula assa-foetida*, Type 2 Diabetes Mellitus, Clinical Trial, Hepatic Function, hs-CRP

1. Background

Type 2 diabetes mellitus (T2DM) is a metabolic disease with complex causes, manifestations, and complications (1). The disease is characterized by insulin resistance and the destruction of β -cells in connection with inflammation (2). The genus *Ferula* is an herbaceous plant belonging to the Apiaceae family. It contains more than 170 species distributed in Central Asia, Eastern Iran, and Afghanistan. One of the Persian names for this plant is Anghuzeh (3).

Animal studies have shown that *Ferula assa-foetida* extract has protective therapeutic effects in diabetes by lowering plasma glucose levels and increasing serum insulin levels in diabetic rats (4). In addition, oral administration of assa-foetida at doses of 1.25% and 2.5% w/w significantly restored the level of the depleted antioxidant system in Sprague-Dawley rats and significantly inhibited lipid peroxidation in the liver of rats (5). Administration of *F. assa-foetida* resin has also shown effects in preventing hepatic steatosis in type 2 diabetic rats, associated with decreased serum leptin levels (6).

From the perspective of the mechanism, the anti-diabetic effect of *F. assa-foetida* can be mediated by its protective role in pancreatic β -cell membrane integrity (4) and its antioxidant activities due to its high content of total phenols and flavonoids, including phenolic acid gallic and flavonoids such as quercetin. Additionally, the extract of this plant has shown different levels of antioxidant activity in the laboratory, including the ability to chelate with iron ions (Fe^{2+}) and eliminate diphenyl-2-picryl hydrazyl (DPPH) and nitric oxide free radicals (7). However, more detailed studies of assa-foetida properties require clinical trials (3).

2. Objectives

Due to the lack of clinical trial studies examining the effect of *F. assa-foetida* in diabetic patients, we aimed to evaluate the anti-hyperglycemic, anti-hyperlipidemic, anti-inflammatory, and antioxidant effects of the herbal drug *F. assa-foetida* (assa-foetida) in patients with type 2 diabetes.

3. Methods

3.1. Subjects, Study Design, and Protocol

This study was designed as a randomized, double-blinded, placebo-controlled trial conducted at Ayatollah

Taleghani Hospital, Abadan University of Medical Sciences, Abadan, Iran. The study adhered strictly to the clinical research guidelines of the Government of Iran, following the protocol approved by the registered Ethical Committee (ethic code: [IR.ABADANUMS.REC.1398.024](#)) dated 2019-06-16. Additionally, this clinical trial has been approved by the Iranian Registry of Clinical Trials (IRCT registration number: [IRCT20190525043704N1](#)) dated 2019-09-23.

The subjects were selected from patients who visited the doctor for medical advice about type 2 diabetes. Those subjects who fulfilled the seven screening criteria under the widely used Wilson-Jugner criteria were enrolled in the study with written informed consent (8, 9). The protocol applied in the present study is illustrated in Figure 1. The total study period was 90 days.

During the first visit on day 0, an internal specialist physician screened the adult patients with T2DM to participate in the study, taking into account the inclusion and exclusion criteria. During the second visit (day 1), the basic characteristics of the patients and the anthropometric measurements, including height (H, cm), weight (W, kg), waist circumference (WC, cm), and hip circumference (HC, cm), were obtained using a stadiometer, a digital scale (Omron, BF511, OMRON HEALTHCARE Co., Ltd. Kyoto, Japan), and a tape measure, respectively. In addition, Body Mass Index (BMI; kg/m^2) was calculated by dividing weight by height squared, and WHR was obtained by dividing WC by HC. Moreover, systolic and diastolic blood pressures (mmHg) were evaluated using an automatic blood pressure monitor (Model M6 AC, OMRON HEALTHCARE Co., Ltd. Kyoto, Japan).

On the third visit (day 2), patients were divided into assa-foetida and Placebo groups. The intervention group received polyethylene containers containing 180 capsules labeled assa-foetida at a dose of 250 mg twice daily, and the control group received polyethylene containers containing 180 starch capsules at a dose of 250 mg twice daily as a placebo. Patients were instructed to take one capsule before breakfast and one capsule before dinner (250 mg twice daily) (10). At the end of the study, the compliance rate of prescriptions was assessed using the pill-counting strategy.

All subjects in both the intervention and control groups continued receiving their current hypoglycemic drugs, glibenclamide, and metformin, during the study. During the third (day 2) and the fourth visits (day 90), 8




Figure 1. Participant follow diagram illustrating study design

cc of blood was drawn when the patient had been fasting for at least 8 and at most 16 hours for biochemical analysis.

3.2. Inclusion and Exclusion Criteria

Our inclusion criteria were age 25 - 70 years, male and female patients, fulfilling diagnostic criteria for T2DM (11), and willing to provide written informed consent.

Exclusion criteria included the consumption of warfarin and other Coumarin substitutes by the patient; use of blood glucose-boosting drugs such as antidepressants (Tricyclics), beta-adrenergic blockers, corticosteroids, diazoxide, diuretics, epinephrine, estrogen, glucagon, isoniazid, lithium, phenothiazines,

phenytoin, salicylates, and triamterene; use of blood glucose-lowering drugs including acetaminophen, alcohol, anabolic steroids, gemfibrozil, monoamine oxidase inhibitors, propranolol, tolazamide, and tolbutamide; history of uncontrolled hypertension, congestive heart failure, and other cardiovascular diseases, liver, kidney, or any metabolic and clinical disorders other than T2DM; pregnancy and lactation in women; psychological diseases; being treated with insulin; smoking during the test period (as it raises blood glucose levels); having sickle cell anemia, thalassemia, and chronic renal failure that affect hemoglobin A1c levels; and any circumstances that, in the opinion of the researcher, do not support the participation of patients in the study (10).

3.3. Randomization and Blinding

3.3.1. Creating a Random Sequence

In this study, random sampling was performed using a random numbers table to create a random sequence based on the method described in the Vaidyanathan study (12).

3.3.2. Allocation Concealment

Opaque, sealed, and waxed envelopes were used sequentially to hide random allocation (numbered, sealed, opaque envelopes). In this method, after creating a random sequence, based on the research sample size, several envelopes with aluminum wrapping (to obscure the contents of the envelopes) were prepared. Each of the created random sequences was recorded on a card, and the cards were placed in the envelopes to preserve the random sequence. The outside of the envelopes was numbered in the same order. Finally, the envelopes were sealed and placed inside a box. The envelopes were opened in order, and the assigned group of that participant was revealed. One of the researchers prepared supplements or capsules with the same color and shape (placebo) and placed them in the envelope according to the allocation order. These supplements could not be distinguished because they contained cans with the same color, shape, and label.

3.3.3 Implementing the Random Allocation Process

In this study, the researcher who created the random sequence was separated from other researchers during the stage of registering the names or allocation of participants to reduce possible bias.

3.3.4 Blinding

This study was conducted in a double-blind manner. In this way, both the participants and the researchers were unaware of the allocation of the study groups. The placebos were completely similar to the *F. assa-foetida* supplement in terms of color, appearance of the cans, gelatin capsules, smell, and the method of use that was included on the placebo cans so that study participants were blind about the allocated group.

3.4. Primary Outcome

The primary outcomes included changes in: (1) Glucose metabolism, which was measured by fasting, two-hour postprandial, and HbA1c; (2) hepatic function,

which was evaluated by liver function tests; (3) oxidative stress, which was assessed by antioxidant enzyme activity; (4) complications of chronic hyperglycemia, which were evaluated by advanced glycation end product (AGE) formation, from baseline to 90 days of follow-up in the *assa-foetida* group compared with placebo.

3.5. Secondary Outcome

The secondary outcome was determined based on the effect of *assa-foetida* compared with placebo on the comorbidities of diabetes [anthropometric measurements, blood lipid concentrations, blood pressure, leptin, and high-sensitive C-reactive protein (hs-CRP) concentrations] at baseline and 90 days after *assa-foetida* administration.

3.6. Preparation and Formulation of the Assa-foetida and Placebo

Iranian *F. assa-foetida* was employed for the preparation of *assa-foetida* capsules. The root and stem of *F. assa-foetida* L. were purchased from a local medicinal plant market in Kerman, Iran. The combination of drug formulations used in the same study (13) (plant roots and seeds) was used to prepare *assa-foetida* capsules in the Department of Pharmacology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences with Herbarium Voucher Number 981, and then they were formed into capsules in a dose of 250 mg.

3.7. Safety Assessment of Ferula assa-foetida and Side Effects

Ferula assa-foetida drug toxicity at a dose of 250 mg twice daily has been confirmed based on a previous study. Moreover, the use of this medicinal plant in humans has not shown any side effects (13).

3.8. Biochemical Assessment

The calorimetric method using a spectrophotometric device was used to measure glycemic and lipid profiles, and hepatic enzyme activity. The activity of catalase, serum levels of hs-CRP, and MDA was measured by the calorimetric method with an ELISA reader. Measurement of AGEs and leptin serum levels was performed by the ELISA method with an ELISA reader.

3.9. Dietary Assessment

To evaluate dietary intake, a Qualitative Food Frequency Questionnaire (FFQ) was used (14). The FFQ

was completed for all patients during the second visit (day 1) and the fourth visit (day 90). Based on previous studies, the food items on the FFQ were grouped according to their nutrient contents (14, 15). Therefore, seventeen food groups were derived as follows: (1) Whole grains, (2) refined grains, (3) potatoes, (4) dairy products, (5) vegetables, (6) fruits, (7) legumes, (8) meats, (9) nuts and seeds, (10) solid fat, (11) liquid oil, (12) tea and coffee, (13) salty snacks, (14) simple sugars, (15) honey and jams, (16) soft drinks, and (17) desserts and snacks. Possible response categories were “daily”, “weekly”, “monthly”, “annually”, and “never”. The responses were scored according to a researcher-based scoring system as follows: “daily: 4”, “weekly: 3”, “monthly: 2”, “annually: 1”, and “never: 0”. Responses were added to determine the score of consumption frequency of each food group.

3.10. Assessment of Physical Activity

An assessment of physical activity (PA) was performed using a short version of the International Physical Activity Questionnaire (IPAQ) in the “last 7 days” during the second visit (day 1), and the interpretation of the results was based on a procedure explained in the Mynarski et al. study (16).

3.11. Sample Size Calculation

We used a similar study for the calculation of sample size (10). The number of samples in each group was calculated taking into account $\delta_1 = 2.50$, $\mu_1 = 89.92$, $\delta_2 = 2.57$, $\mu_2 = 95.11$, $\alpha = 0.05$, and power 90%, resulting in 6 patients. The sample size calculation was performed based on the formula as below (17):

$$n_i = \frac{\left(Z_{1-\frac{\alpha}{2}} + Z_{1-\beta}\right)^2 \times 2\sigma_{pooled}^2}{(\mu_A - \mu_B)^2} \quad (1)$$

$$\sigma_{pooled}^2 = \frac{(n_A - 1)s_A^2 + (n_B - 1)s_B^2}{(n_A + n_B - 2)} \quad (2)$$

We have decided to include a total of 20 patients, with 10 patients in each group, to ensure statistical robustness in our analysis.

3.12. Statistical Analyses

Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA) version 26. Data normality was checked by the Shapiro-Wilk test. For normally distributed data, a paired sample *t*-test was

used for within-group comparison of a specific parameter, and between-group comparison of that parameter was performed using an independent *t*-test. For non-normally distributed data, the Wilcoxon Signed Ranks test was applied for within-group comparison of a specific parameter, and the Mann-Whitney U test was used for between-group comparison of that parameter. Moreover, differences in the frequency of variables were compared using the chi-square (χ^2) test. The results are displayed as mean and standard deviation (mean \pm SD) for normal distribution parameters and median (IQR) for non-normal distribution parameters.

4. Results

4.1. Baseline Characteristics of Participants

The baseline characteristics are provided in Table 1. No significant differences were found between placebo and assa-foetida-treated groups in demographic characteristics at baseline.

4.2. Follow-up and Adherence

There were no significant group differences in adherence to the assigned treatment, as determined by pill counts. In the assa-foetida group, 5 (50%) of those with 90 days' data had $\geq 80\%$ compliance compared with 5 (71.4%) in the placebo group ($P = 0.515$).

4.3. Effect of Assa-foetida on Physical Activity, Anthropometric, and Clinical Characteristics

4.3.1. Physical Activity Parameters

The present study employed an IPAQ Scale to compare weekly PA measurements in the assa-foetida and placebo groups at baseline and the end of the study. Between-group comparison using the Mann-Whitney U test showed no significant difference between baseline values of the placebo and assa-foetida-treated groups for weekly PA of low intensity. However, declared weekly PA was significantly higher among patients receiving assa-foetida compared with the placebo-treated group at baseline [between-group mean difference of weekly PA of low intensity: -2715.08 METmin/week; 95% CI: -5758.58, 328.43, $P = 0.077$; between-group mean difference of declared weekly PA: -3540.06 METmin/week, 95% CI: -6714.47, -365.64; $P = 0.031$]. However, there was no significant difference at the end of study values when compared to the placebo.

Table 1. Baseline Demographic Characteristics of Study Subjects ^a

Characteristics	Placebo (N = 10)	Assa-foetida (N = 10)	P-Value
Age (y)	52.4 ± 5.9	49.4 ± 8.2	0.362 ^b
Sex (male)	2 (20)	4 (40)	0.314 ^c
Education			0.819 ^c
Ignorant	2 (20)	1 (10)	
Under-diploma and diploma	7 (70)	8 (80)	
Academic education	1 (10)	1 (10)	

^a Values are expressed as mean ± standard deviation (SD) for quantitative and No. (%) for qualitative data.

^b Independent samples *t*-test was applied to analyze quantitative and qualitative data, respectively.

^c Chi-square test was applied to analyze quantitative and qualitative data, respectively.

4.3.2. Anthropometric and Clinical Characteristics

No significant differences were observed between the groups in terms of weight or clinical characteristics at baseline or study end, as determined by the paired sample *t*-test/Wilcoxon Signed Ranks test (Table 2).

4.4. Effect of Assa-foetida on Glycemic, Lipidemic, Hepatic, Inflammatory, and Antioxidant Parameters

4.4.1. Inflammatory Markers (ESR and High-Sensitive C-Reactive Protein)

Assa-foetida increased ESR levels at the end of the study compared to baseline. As Table 3 shows, a within-group comparison using the Wilcoxon Signed Ranks test displayed a significant increase in the end-of-study values of ESR 1st h (mm/h) compared to the baseline in the assa-foetida treated group [within-group mean difference of ESR 1st h (mm/h): -4.8 mm/h, 95% CI: -8.7, -0.84; *P* = 0.017]. However, this increase was within the normal range (< 20 mm/h). In addition, the Mann-Whitney U test showed that patients in the placebo-treated group had higher ESR 1st h (mm/h) values at baseline compared to the assa-foetida group.

In addition, lower hs-CRP levels were found in the placebo group compared to baseline. A within-group comparison using the paired sample *t*-test showed a lower hs-CRP value in placebo-treated groups at the end of the study compared to baseline [within-group mean difference of hs-CRP (mg/L): 1.9, 95% CI: 0.5, 3.3; *P* = 0.015].

4.4.2. Lipid Profile (HDL-C)

A decrease in HDL-C levels was observed in the assa-foetida group by the study's end based on the paired

sample *t*-test [within-group mean difference of HDL-C (mg/dL): 7.7, 95% CI: 0.2, 14.2; *P* = 0.046].

4.4.3. Liver Enzyme (Serum Glutamic Pyruvic Transaminase)

Furthermore, a between-group comparison using the Mann-Whitney U test revealed that patients in the assa-foetida-treated group showed higher serum glutamic pyruvic transaminase (SGPT) compared to the placebo-treated group at the end of the study [between-group mean difference of SGPT (IU/L): -7.71 IU/L, 95% CI: -13.92, -1.49; *P* = 0.036]. However, this increase was within the normal range (5 - 40 IU/L).

4.4.4. Glucose Metabolism

There was no significant difference in the glycemic profile and antioxidant parameters between the assa-foetida and placebo groups at baseline and the end of the study.

4.5. Dietary Assessment of Placebo and Assa-foetida Treated Groups at Baseline and After 90-Day Follow-up

Between-group comparison based on an independent sample *t*-test indicated that the mean score of taking nuts and seeds (between-group mean difference of taking nuts and seeds: 4.3, 95% CI: -0.4, 8.3; *P* = 0.033) and desserts and snacks (between-group mean difference of taking snacks and desserts: 9.1, 95% CI: 1.7, 16.6; *P* = 0.021) food groups reported on FFQs were significantly lower in the assa-foetida group than in the placebo group on day 90 of the study.

Moreover, within-group comparison based on the paired sample *t*-test/Wilcoxon Signed Ranks test revealed that intakes from whole grains (within-group mean difference of taking whole grains: 12.9, 95% CI: 7.1, 18.6; *P* = 0.018), refined grains (within-group mean

Table 2. Statistical Comparison of Anthropometric, Clinical, and Physical Activity Parameters Between Patients in Placebo and Assa-foetida Capsule Groups Before and After the Intervention ^a

Parameters	Placebo	Assa-foetida	P-Value ^b
Weight (kg)			
Baseline	78.3 ± 11.1	79.7 ± 11.1	0.772
Day 90	80.2 ± 12.5	79.8 ± 11.2	0.953
P-value ^c	0.731	0.701	-
BMI (kg/m²)			
Baseline	30.9 ± 4.8	29.8 ± 3	0.55
Day 90	30.4 ± 4.9	29.7 ± 2.8	0.732
P-value ^c	0.908	0.553	-
WC (cm)			
Baseline	105.6 ± 8.4	104.6 ± 8.3	0.794
Day 90	104.6 ± 10.3	104.9 ± 10.4	0.951
P-value ^c	0.467	0.952	-
WHR			
Baseline	0.89 ± 0.3	0.97 ± 0.04	0.408
Day 90	0.97 ± 0.04	0.99 ± 0.04	0.337
P-value ^c	0.29	0.354	-
Systolic BP (mmHg)			
Baseline	147.1 ± 24.8	119.4 ± 42.6	0.092
Day 90	142 ± 27.8	125.7 ± 14.1	0.154
P-value ^c	0.798	0.401	-
Diastolic BP (mmHg)			
Baseline	90.1 ± 9.4	77.3 ± 25.6	0.156
Day 90	89.2 ± 12.3	86.9 ± 10.8	0.711
P-value ^c	0.949	0.297	-
PA1 ^d (METmin/wk) ^e			
Baseline	0 (0.6)	0 (10.9)	0.315
Day 90	0 (39)	0 (364)	0.607
P-value ^c	0.285	0.575	-
PA2 ^f (METmin/wk) ^e			
Baseline	32 (141.8)	60 (658.5)	0.28
Day 90	40.2 (597.2)	72 (360)	0.864
P-value ^c	0.138	0.889	-
PA3 ^g (METmin/wk) ^e			
Baseline	74.3 (1454.1)	1386 (4393.1)	0.011
Day 90	635.3 (1163.3)	693 (3729)	0.529
P-value ^c	0.463	0.173	-
DPA ^e (METmin/wk) ^e			
Baseline	238.6 (1578.6)	3017.8 (5915.1)	0.011
Day 90	695.3 (1619.4)	1632 (5030.5)	0.456
P-value ^c	0.6	0.214	-

Abbreviations: BMI, Body Mass Index; WC, waist circumference; WHR, waist to hip ratio; PA, physical activity.

^a Values are expressed as mean ± standard deviation (SD) for normal and median (IQR) for non-normal distribution.^b Between-group comparisons were applied based on the independent sample *t*-test/Mann-Whitney U test.^c Within-group comparisons were applied based on the paired sample *t*-test/Wilcoxon Signed Ranks test.^d Weekly PA of high intensity.^e Non-parametric tests were applied to analyze data.^f Weekly PA of moderate intensity.^g Weekly PA of low intensity.

difference of taking refined grains: -7, 95% CI: -13.3, -0.7; *P* = 0.034), and potatoes (within-group mean difference of taking potatoes: -4, 95% CI: -7.2, -0.8; *P* = 0.028) food groups were increased significantly on day 90 compared to the baseline among patients taking assa-foetida. However, patients taking assa-foetida consumed more nuts and seeds at baseline compared to day 90 (within-group mean difference of taking nuts and seeds: 2.2, 95% CI: 0.2, 4.2; *P* = 0.041) on day 90 compared to the baseline.

At the same time, the patients in the placebo group consumed more refined grains (within-group mean

difference of taking refined grains: -6.3, 95% CI: -10.6, -2.1; *P* = 0.012) and legumes (within-group mean difference of taking legumes: -4.7, 95% CI: -8.8, -0.49; *P* = 0.035) (Table 4).

5. Discussion

The findings of the present study showed that assa-foetida increased ESR values and decreased HDL-C serum levels at the end of the study compared to baseline. In addition, lower hs-CRP values were found in placebo-treated groups at the end of the study compared to baseline. Furthermore, assa-foetida increased the value

of SGPT compared with the placebo at the end of the study.

5.1. Inflammatory Markers (ESR and High-sensitive C-Reactive Protein)

Assa-foetida increased ESR levels at the end of the study compared to baseline. Moreover, lower hs-CRP levels were found in the placebo group compared to baseline. These changes might reflect the influence of the patients' dietary habits, particularly low nut and seed consumption and high refined grain intake in the assa-foetida group.

Several in-vivo studies have demonstrated the protective effect against tissue damage due to the antioxidant capacity, anti-hyperglycemic potential, and ability to regenerate β -cells of various species of *Ferula* in animal models of diabetes mellitus (4, 18-21). However, to our knowledge, this is the first clinical trial regarding the anti-diabetic potentials of *F. assa-foetida*. An increased ESR value in the assa-foetida-treated group at the end of the study compared to baseline and lower hs-CRP values in placebo-treated groups at the end of the study compared to baseline can be attributed to the negative effect of the common dietary pattern of the patients evaluated by FFQs on the observed outcomes related to T2DM. Believing that regular nut consumption and substituting nuts for refined grains may lead to a decrease in circulating levels of pro-inflammatory markers such as ESR (22) and CRP (23), it seems rational that less frequent consumption of nuts and seeds and more frequent consumption of refined grains in patients treated with assa-foetida on day 90 compared to baseline have negatively impacted the results of our study.

5.2. Lipid Profile (HDL-C)

A decrease in HDL-C levels was found in the assa-foetida group by the study's end. The T2DM often comes with decreased levels of HDL-C, which adds to the heightened cardiovascular risk linked to this condition. Since HDLs can enhance glucose absorption by skeletal muscle and promote insulin secretion from pancreatic beta cells, it is possible that low HDL levels in type 2 diabetes might also worsen the management of the disease (24). Besides, dietary data showed a higher carbohydrate consumption (e.g., whole grains, refined grains, and potatoes) in the assa-foetida group, which might contribute to decreased HDL; as a low-carbohydrate diet is generally associated with improved HDL-C levels in T2DM (25). Moreover, diets rich in whole-

grain foods tend to raise serum HDL-C levels. Whole-grain intake may also favorably modify antioxidant and inflammatory states. Whole-grain components that appear to make major contributions to these protective effects include dietary fiber, vitamins, minerals, antioxidants, phytosterols, and other phytochemicals (26).

The present study found no significant differences between assa-foetida and placebo-treated groups in the anthropometric and clinical characteristics of the patients at baseline and the end of the study period. An experimental study found evidence consistent with our finding, as prolonged oral administration of *F. assa-foetida* extracts at a dose of 250 mg/kg for 28 days did not show any significant alterations in body weight and body weight gain (27). The outcomes suggest that assa-foetida supplementation alone may not be sufficient to yield significant anti-inflammatory or antioxidant benefits. Positive dietary modifications, such as increased nut and seed consumption and reduced refined grain intake, could enhance the efficacy of the herb.

5.3. Liver Enzyme (Serum Glutamic Pyruvic Transaminase) and Safety Profile

The SGPT levels increased in the assa-foetida group compared to placebo, though they remained within the normal range (5 - 40 IU/L). This aligns with some experimental findings on mild hepatic changes associated with assa-foetida use (28, 29). Increased ALT was utilized as a proxy marker for Nonalcoholic Fatty Liver Disease (NAFLD), indicating that this condition might be prevalent among those with T2DM. Elements of metabolic syndrome, which frequently occurs prior to T2DM, such as obesity, hyperinsulinemia, insulin resistance, elevated triglyceride levels, and high blood pressure, have been suggested as potential contributors to NAFLD in previous research. This research aligns with the existing comprehension of NAFLD's development as a liver-related aspect of metabolic syndrome, as elevated ALT levels were prevalent among individuals diagnosed with T2DM, indicating that the emergence of NAFLD might occur before the onset of T2DM (30).

An experimental study observed little toxicity in the short-term use of *F. assa-foetida* extract and displayed mild changes by way of thrombosis, sinusoidal leukocytosis, and portal infiltration with inflammatory cells in the liver of treated rats, which showed a normal histological structure of the hepatic lobule, consistent with our study (27).

Regardless of the higher SGPT serum levels in the *assa-foetida*-treated group compared to the placebo at the end of the study, these levels were within the normal range (5 - 40 IU/L) before and after the study. Considering the common alteration in liver enzyme levels of T2DM patients (31), the increase in SGPT and ESR levels, though within normal ranges, raises concerns about potential hepatic and inflammatory effects. Lower doses may be more suitable for reducing these risks.

5.4. Glucose Metabolism, Comorbidities, and Dose Consideration

In this study, no significant differences in glucose metabolism or diabetes-related comorbidities were found between the *assa-foetida* and placebo groups. Previous studies have shown mixed results on the anti-hyperglycemic and anti-lipidemic effects of *F. assa-foetida*, often depending on the dosage, extraction methods, and duration of testing (20, 32, 33). It is well established that hyperglycemia and hyperlipidemia are common symptoms of T2DM, leading to modification of glucose and lipid metabolism and changes in liver enzyme levels (34).

Additionally, it has been established that ferulic acid is one of the phenolic phytochemical components found abundantly in *assa-foetida* (35), which has exhibited antidiabetic potential in animal models of diabetes by elevating insulin secretion (36), preventing intestinal α -glucosidase (37), and activating glucokinase (38). Even though hyperglycemia and hyperlipidemia are more common in supplementation with high doses (HD) than low doses (LD) of *F. assa-foetida*, the prescribed dose of 250 mg twice daily might have been too high. Evidence suggests that lower doses of ferulic acid may provide better glycemic and lipid control while minimizing adverse effects in diabetic models (20, 33, 39, 40).

5.5. Conclusions

Ferula assa-foetida supplementation at 250 mg twice daily increased ESR and SGPT levels (within normal ranges) and decreased HDL-C serum levels in T2DM patients. Combining *assa-foetida* with positive dietary changes may enhance its anti-inflammatory and antioxidant benefits. Lower doses (< 250 mg twice daily) could reduce potential hepatic and inflammatory complications. Future research with a larger sample size and more robust dietary interventions is recommended to confirm these findings. This study contributes to the

growing body of research on the clinical potential of *F. assa-foetida*, while emphasizing the need for a holistic approach combining supplementation with dietary improvements for better management of T2DM.

5.6. Study Strength and Limitations

The strength of this study was the long duration of treatment to evaluate the long-term efficacy of *F. assa-foetida* in T2DM management. However, the study's small sample size and the impact of the COVID-19 pandemic on enrollment limit the generalizability of the findings (41). A larger clinical trial is recommended to further evaluate the efficacy and safety of *F. assa-foetida*.

Acknowledgements

The authors would like to thank all the study subjects for their participation.

Footnotes

Authors' Contribution: S. G. and M. N. conceived the study and designed the experiments. S. G., M. A., M. N., and A. Kh. performed experiments and collected data. N. K., S. G., and M. N. analyzed and interpreted results. S. G. and M. N. prepared the draft manuscript. M. N. supervised and managed the study. all authors reviewed the results and approved the final version to be published.

Clinical Trial Registration Code: This trial has been approved by the Iranian Registry of Clinical Trials (IRCT20190525043704N1).

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The data supporting this research are original. The processed data are available from the corresponding author upon reasonable request.

Ethical Approval: The study was in strict accordance with the clinical research guidelines of the government of Iran following the protocol approved by the registered Ethical Committee (IR.ABADANUMS.REC.1398.024) dated 2019-06-16.

Funding/Support: This work was supported by the Vice Chancellor for Research, Abadan University of Medical Sciences (grant numbers 97U-524).

Informed Consent: Written informed consent was obtained from the participants.

References

- Gholipour K, Asghari-Jafarabadi M, Iezadi S, Jannati A, Keshavarz S. Modelling the prevalence of diabetes mellitus risk factors based on artificial neural network and multiple regression. *East Mediterr Health J.* 2018;**24**(8):770-7. [PubMed ID: 30328607]. <https://doi.org/10.26719/emhj.18.012>.
- Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. *mBio.* 2018;**9**(3). [PubMed ID: 29789365]. [PubMed Central ID: PMC5964358]. <https://doi.org/10.1128/mBio.02392-17>.
- Mahendra P, Bisht S. Ferula asafoetida: Traditional uses and pharmacological activity. *Pharmacogn Rev.* 2012;**6**(12):141-6. [PubMed ID: 23055640]. [PubMed Central ID: PMC3459456]. <https://doi.org/10.4103/0973-7847.99948>.
- Abu-Zaiton AS. Anti-diabetic activity of Ferula assafoetida extract in normal and alloxan-induced diabetic rats. *Pak J Biol Sci.* 2010;**13**(2):97-100. [PubMed ID: 20415145]. <https://doi.org/10.3923/pjbs.2010.97.100>.
- Mallikarjuna GU, Dhanalakshmi S, Raisuddin S, Rao AR. Chemomodulatory influence of Ferula asafoetida on mammary epithelial differentiation, hepatic drug metabolizing enzymes, antioxidant profiles and N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. *Breast Cancer Res Treat.* 2003;**81**(1):1-10. [PubMed ID: 14531492]. <https://doi.org/10.1023/a:1025448620558>.
- Azizian H, Ebrahim Rezvani M, Esmaeilidehaj M, Bagheri SM. Anti-Obesity, Fat Lowering and Liver Steatosis Protective Effects of Ferula asafoetida Gum in Type 2 Diabetic Rats: Possible Involvement of Leptin. *Iran J Diabetes Obesity.* 2012;**4**(3):120-6.
- Dehpour AA, Ebrahimzadeh MA, Seyed Fazel N, Seyed Mohammad N. Antioxidant activity of the methanol extract of Ferula assafoetida and its essential oil composition. *Grasas y Aceites.* 2009;**60**(4):405-12. <https://doi.org/10.3989/gya.010109>.
- Kaur G, Lakshmi PVM, Rastogi A, Bhansali A, Jain S, Teerawattananon Y, et al. Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis. *PLoS One.* 2020;**15**(11). e0242415. [PubMed ID: 33216783]. [PubMed Central ID: PMC7678987]. <https://doi.org/10.1371/journal.pone.0242415>.
- Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. *Bol Oficina Sanit Panam.* 1968;**65**(4):281-393. ES. [PubMed ID: 4234760].
- Mala KN, Thomas J, Syam DS, Maliakel B, Krishnakumar IM. Safety and Efficacy of Ferula asafoetida in Functional Dyspepsia: A Randomized, Double-Blinded, Placebo-Controlled Study. *Evid Based Complement Alternat Med.* 2018;**2018**:4813601. [PubMed ID: 30224930]. [PubMed Central ID: PMC6129344]. <https://doi.org/10.1155/2018/4813601>.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care.* 2018;**41**(Suppl 1):S13-27. [PubMed ID: 29222373]. <https://doi.org/10.2337/dc18-S002>.
- Vaidyanathan AK. Randomization in clinical research. *J Indian Prosthodont Soc.* 2024;**24**(1):1-2. [PubMed ID: 38263552]. [PubMed Central ID: PMC10896307]. https://doi.org/10.4103/jips.jips_545_23.
- Kassir E, Fulder S, Khalil K, Hadieh B, Nahhas F, Saad B, et al. Efficacy and safety assessments of Ferula assa-foetida L., traditionally used in Greco-Arab herbal medicine for enhancing male fertility, libido and erectile function. *Open Complement Med J.* 2009;**1**(1):102-9.
- Esfahani FH, Asghari G, Mirmiran P, Azizi F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. *J Epidemiol.* 2010;**20**(2):150-8. [PubMed ID: 20154450]. [PubMed Central ID: PMC3900814]. <https://doi.org/10.2188/jea.je20090083>.
- Hu FB, Rimm E, Smith-Warner SA, Feskanich D, Stampfer MJ, Ascherio A, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. *Am J Clin Nutr.* 1999;**69**(2):243-9. [PubMed ID: 9989687]. <https://doi.org/10.1093/ajcn/69.2.243>.
- Mynarski W, Psurek A, Borek Z, Rozpara M, Grabara M, Strojek K. Declared and real physical activity in patients with type 2 diabetes mellitus as assessed by the International Physical Activity Questionnaire and Caltrac accelerometer monitor: a potential tool for physical activity assessment in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2012;**98**(1):46-50. [PubMed ID: 22749774]. <https://doi.org/10.1016/j.diabres.2012.05.024>.
- Chow S, Shao J, Wang H, Lokhnygina Y, Chow S, Shao J, et al. *Sample Size Calculations in Clinical Research: Third Edition.* Boca Raton, Florida: CRC Press; 2017. <https://doi.org/10.1201/9781315183084>.
- Latifi E, Mohammadpour AA, Fathi Hafshejani B, Nourani H. Ferula assa-foetida oleo gum resin ethanolic extract alleviated the pancreatic changes and antioxidant status in streptozotocin-induced diabetic rats: A biochemical, histopathological, and ultrastructural study. *J Food Biochem.* 2022;**46**(8). e14191. [PubMed ID: 35474229]. <https://doi.org/10.1111/jfbc.14191>.
- Uyar A, Yaman T, Keles OF, Alkan EE, Demir A, Celik I, et al. Reduction of hepatorenal and pancreatic damage by Ferula elaeochoyris extract in STZ induced diabetic rats. *Biotech Histochem.* 2021;**96**(1):28-40. [PubMed ID: 32396744]. <https://doi.org/10.1080/10520295.2020.1753239>.
- Latifi E, Mohammadpour AA, H BF, Nourani H. Antidiabetic and antihyperlipidemic effects of ethanolic Ferula assa-foetida oleo-gum-resin extract in streptozotocin-induced diabetic wistar rats. *Biomed Pharmacother.* 2019;**110**:197-202. [PubMed ID: 30471513]. <https://doi.org/10.1016/j.biopha.2018.10.152>.
- Eser N, Buyuknacar HS, Cimentepe OO, Gocmen C, Ucar Y, Erdogan S, et al. The effect of Ferula elaeochoyris root extract on erectile dysfunction in streptozotocin-induced diabetic rat. *Int J Impot Res.* 2020;**32**(2):186-94. [PubMed ID: 30979969]. <https://doi.org/10.1038/s41443-019-0137-8>.
- Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Giannini EG. Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? *Nutrients.* 2020;**12**(11). [PubMed ID: 33139607]. [PubMed Central ID: PMC7693493]. <https://doi.org/10.3390/nu12113363>.
- Yu Z, Malik VS, Keum N, Hu FB, Giovannucci EL, Stampfer MJ, et al. Associations between nut consumption and inflammatory biomarkers. *Am J Clin Nutr.* 2016;**104**(3):722-8. [PubMed ID: 27465378]. [PubMed Central ID: PMC4997300]. <https://doi.org/10.3945/ajcn.116.134205>.
- Barter PJ. The causes and consequences of low levels of high density lipoproteins in patients with diabetes. *Diabetes Metab J.* 2011;**35**(2):101-6. [PubMed ID: 21738891]. [PubMed Central ID: PMC3122896]. <https://doi.org/10.4093/dmj.2011.35.2.101>.
- Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr.* 2015;**102**(4):780-90. [PubMed ID: 26224300]. <https://doi.org/10.3945/ajcn.115.112581>.

26. Anderson JW. Whole grains protect against atherosclerotic cardiovascular disease. *Proc Nutr Soc.* 2003;**62**(1):135-42. [PubMed ID: 12740068]. <https://doi.org/10.1079/PNS2002222>.
27. Goudah A, Abdo-El-Sooud K, Yousef MA. Acute and subchronic toxicity assessment model of *Ferula assa-foetida* gum in rodents. *Vet World.* 2015;**8**(5):584-9. [PubMed ID: 27047139]. [PubMed Central ID: PMC4774717]. <https://doi.org/10.14202/vetworld.2015.584-589>.
28. Deniz GY, Laloglu E, Koc K, Geyikoglu F. Hepatoprotective potential of *Ferula communis* extract for carbon tetrachloride induced hepatotoxicity and oxidative damage in rats. *Biotech Histochem.* 2019;**94**(5):334-40. [PubMed ID: 30712392]. <https://doi.org/10.1080/10520295.2019.1566831>.
29. Illuri R, Venkataramana SH, Daguet D, Kodimule S. Sub-acute and acute toxicity of *Ferula asafoetida* and *Silybum marianum* formulation and effect of the formulation on delaying gastric emptying. *BMC Complement Altern Med.* 2019;**19**(1):159. [PubMed ID: 31277639]. [PubMed Central ID: PMC6612090]. <https://doi.org/10.1186/s12906-019-2576-7>.
30. Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control. *Indian J Endocrinol Metab.* 2012;**16**(6):1012-4. [PubMed ID: 23226654]. [PubMed Central ID: PMC3510928]. <https://doi.org/10.4103/2230-8210.103027>.
31. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). *J Diabetes Res.* 2020;**2020**:3920196. [PubMed ID: 32832560]. [PubMed Central ID: PMC7424491]. <https://doi.org/10.1155/2020/3920196>.
32. Yusufoglu HS, Soliman GA, Rahman RF, Abdel-Kade MS, Ganaie MA, Bedir E, et al. Antihyperglycemic and Antihyperlipidemic Effects of *Ferula assa-foetida* and *Ferula tenuissima* Extracts in Diabetic Rats. *Pakistan J Biological Sci.* 2015;**18**(7):314-23. <https://doi.org/10.3923/pjbs.2015.314.323>.
33. Iranshahi M, Alizadeh M. Antihyperglycemic effect of *Asafoetida* (*Ferula assafoetida* Oleo-Gum-Resin) in streptozotocin-induced diabetic rats. *World Appl Sci J.* 2012;**17**(2):157-62.
34. Jayaraman R, Subramani S, Sheik Abdullah SH, Udaiyar M. Antihyperglycemic effect of hesperetin, a citrus flavonoid, attenuates hyperglycemia and exploring the potential role in antioxidant and antihyperlipidemic in streptozotocin-induced diabetic rats. *Biomed Pharmacother.* 2018;**97**:98-106. [PubMed ID: 29080465]. <https://doi.org/10.1016/j.biopha.2017.10.102>.
35. Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review. *Food Chem.* 2008;**109**(4):691-702. [PubMed ID: 26049981]. <https://doi.org/10.1016/j.foodchem.2008.02.039>.
36. Balasubashini MS, Rukkumani R, Viswanathan P, Menon VP. Ferulic acid alleviates lipid peroxidation in diabetic rats. *Phytother Res.* 2004;**18**(4):310-4. [PubMed ID: 15162367]. <https://doi.org/10.1002/ptr.1440>.
37. Adisakwattana S, Chantarasinlapin P, Thammarat H, Yibchok-Anun S. A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase. *J Enzyme Inhib Med Chem.* 2009;**24**(5):1194-200. [PubMed ID: 19772492]. <https://doi.org/10.1080/14756360902779326>.
38. Son MJ, Rico CW, Nam SH, Kang MY. Effect of Oryzanol and Ferulic Acid on the Glucose Metabolism of Mice Fed with a High-Fat Diet. *J Food Sci.* 2010;**76**(1). <https://doi.org/10.1111/j.1750-3841.2010.01907.x>.
39. Sri Balasubashini M, Rukkumani R, Menon VP. Protective effects of ferulic acid on hyperlipidemic diabetic rats. *Acta Diabetol.* 2003;**40**(3):118-22. [PubMed ID: 14605967]. <https://doi.org/10.1007/s00592-003-0099-6>.
40. Ohnishi M, Matuo T, Tsuno T, Hosoda A, Nomura E, Taniguchi H, et al. Antioxidant activity and hypoglycemic effect of ferulic acid in STZ-induced diabetic mice and KK-Ay mice. *Biofactors.* 2004;**21**(1-4):315-9. [PubMed ID: 15630218]. <https://doi.org/10.1002/biof.552210161>.
41. Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. *Hepatology.* 2022;**76**(2):429-44. [PubMed ID: 35133671]. [PubMed Central ID: PMC9288975]. <https://doi.org/10.1002/hep.32403>.

Table 3. Statistical Comparison of Laboratory Parameters Between Placebo and Assa-foetida Groups Before and After the Intervention ^a

Parameters	Baseline	Day 90	P-Value ^b
ESR 1st h (mm/h)			
Placebo	29 (27.3)	19 (23.5)	0.206
Assa-foetida	10.5 (11.3)	12 (8)	0.017
P-value ^c	0.019	0.37	-
FBG (mg/dL)			
Placebo	148.5 ± 65.2	146.5 ± 67.1	0.732
Assa-foetida	148.7 ± 43.2	163.7 ± 49.9	0.316
P-value ^c	0.994	0.555	-
Two hrspp (mg/dL)			
Placebo	247.7 ± 115.2	234.8 ± 96.2	0.996
Assa-foetida	219.9 ± 73.5	241.4 ± 61.6	0.242
P-value ^c	0.528	0.865	-
Hemoglobin A1c (%)			
Placebo	8.2 ± 1.2	8 ± 1.6	1.00
Assa-foetida	8.5 ± 1	8 ± 1.6	0.184
P-value ^c	0.554	0.943	-
Cholesterol (mg/dL)			
Placebo	163 ± 31.1	163.3 ± 47.3	0.754
Assa-foetida	141.3 ± 45.8	129.4 ± 37.2	0.205
P-value ^c	0.231	0.12	-
Triglycerides (mg/dL)			
Placebo	155 (142.3)	169.5 (122.5)	0.674
Assa-foetida	109.5 (98.5)	151 (162)	0.066
P-value ^c	0.075	0.673	-
HDL-C (mg/dL)			
Placebo	40.3 ± 10.5	59.4 ± 46.4	0.235
Assa-foetida	40 ± 10.03	32.3 ± 6.9	0.046
P-value ^c	0.949	0.104	-
LDL (mg/dL)			
Placebo	86 ± 25.1	86.4 ± 40	0.654
Assa-foetida	76.1 ± 31.1	72.3 ± 35.7	0.965
P-value ^c	0.444	0.456	-
LDL-C/HDL-C			
Placebo	2 (1.8)	2.3 (2.4)	0.888
Assa-foetida	2 (1.3)	1.6 (1.8)	0.213
P-value ^c	0.436	0.888	-
Cholesterol/HDL-C			
Placebo	3.9 (1.6)	4 (3.1)	0.833
Assa-foetida	3.6 (1.6)	3.7 (2.1)	0.137
P-value ^c	0.393	0.963	-
SGOT (IU/L)			
Placebo	21.4 ± 7.02	17.8 ± 5.03	0.363
Assa-foetida	26.8 ± 9.4	21.2 ± 5	0.084
P-value ^c	0.163	0.175	-
SGPT (IU/L)			
Placebo	15 (14)	16.5 (7.5)	0.462
Assa-foetida	21 (24)	25 (12)	0.514
P-value ^c	0.063	0.036	-

Parameters	Baseline	Day 90	P-Value ^b
ESR 1st h (mm/h)			
hs-CRP (mg/L)			
Placebo	4.3 ± 2.3	2.4 ± 1.8	0.015
Assa-foetida	2.9 ± 1.9	2.9 ± 2.4	0.933
P-value ^c	0.166	0.667	-
AGEs			
Placebo	169.5 (42.7)	163.4 (49.1)	0.612
Assa-foetida	163.4 (16.8)	164.4 (26)	0.066
P-value ^c	0.541	0.743	-
Catalase			
Placebo	7.5 ± 2.9	9.7 ± 8.1	0.44
Assa-foetida	11.3 ± 4.8	14.4 ± 9	0.37
P-value ^c	0.07	0.278	-
Leptin			
Placebo	26.7 (38.7)	22 (52.8)	0.310
Assa-foetida	12.2 (21.1)	12.6 (28.2)	0.779
P-value ^c	0.541	0.743	-
MDA			
Placebo	86.3 (138.8)	33.1 (30.3)	0.237
Assa-foetida	41 (50.6)	29.8 (11)	0.173
P-value ^c	0.277	0.815	-

Abbreviations: SGPT, serum glutamic pyruvic transaminase; hs-CRP, high-sensitive C-reactive protein; AGEs, advanced glycation end products.

^a Values are expressed as mean ± standard deviation (SD) for normal and median (IQR) for non-normal distribution.

^b Within-group comparison was applied based on the paired sample *t*-test/Wilcoxon Signed Ranks test.

^c Between-group comparison was applied based on the independent sample *t*-test/Mann-Whitney U test.

Table 4. Statistical Comparison of Mean Food Group Intakes Estimated Using Qualitative Food Frequency Questionnaires Between Placebo and ASSA-foetida Groups Before and After the Intervention ^a

Parameters	Placebo	Assa-foetida	P-Value ^b
Whole grains ^c			
Baseline	7.5 (6)	11 (5)	0.145
Day 90	27.5 (10)	23 (3)	0.073
P-value ^d	0.068	0.018	-
Refined grains			
Baseline	15 (4.25)	16 (9.25)	0.963
Day 90	22 (5.5)	20.5 (6)	0.762
P-value ^d	0.012	0.034	-
Potatoes ^c			
Baseline	5 (4.5)	2 (3.75)	0.133
Day 90	5.5 (4.25)	6 (4)	0.864
P-value ^d	0.891	0.028	-
Vegetables			
Baseline	69 (12.5)	71 (17.5)	0.606
Day 90	64 (8.25)	64 (15.5)	0.973
P-value ^d	0.073	0.288	-
Fruits			
Baseline	144 (39)	133 (33.25)	0.328
Day 90	147.5 (55)	116 (64)	0.341
P-value ^d	0.362	0.747	-
Legumes			
Baseline	14.5 (2.5)	12 (5)	0.501
Day 90	20 (5.25)	18 (9)	0.957
P-value ^d	0.035	0.152	-
Dairy products			
Baseline	55.5 (5.5)	60 (17.5)	0.94
Day 90	54.5 (15)	49.5 (17.25)	0.564
P-value ^d	0.643	0.227	-
Meats ^c			
Baseline	74.5 (9.75)	66 (14.5)	0.139
Day 90	71 (18)	55.5 (6.25)	0.052
P-value ^d	0.713	0.104	-
Nuts and seeds			
Baseline	21 (5.25)	22.5 (6.5)	0.878
Day 90	25.5 (6.75)	19 (2.5)	0.033
P-value ^d	0.528	0.041	-
Solid fats			
Baseline	21 (4.75)	23 (7.5)	0.697
Day 90	22 (5.75)	20 (7.5)	0.477
P-value ^d	0.493	0.281	-
Liquid oil			
Baseline	12.5 (4.25)	12.5 (5.75)	0.915
Day 90	12 (5)	11 (3)	0.827
P-value ^d	0.636	0.311	-
Tea and coffee ^c			
Baseline	4 (3)	4 (3)	0.971

Parameters	Placebo	Assa-foetida	P-Value ^b
Whole grains ^c			
Day 90	4 (2.5)	4.5 (1.75)	0.662
P-value ^d	0.748	0.129	-
Salty snacks ^c			
Baseline	16 (6)	15 (6)	1.00
Day 90	14.5 (6)	12 (3)	0.534
P-value ^d	0.223	0.336	-
Simple sugars ^c			
Baseline	16.5 (8.5)	20 (8)	0.182
Day 90	23.5 (7)	20 (6)	0.145
P-value ^d	0.046	0.752	-
Honey and jams ^c			
Baseline	7.5 (4)	7.5 (3)	0.739
Day 90	7.5 (1.75)	7 (3)	0.456
P-value ^d	0.786	0.336	-
Soft drinks ^c			
Baseline	5 (2.25)	4 (2.25)	0.436
Day 90	4 (2.25)	3 (1.75)	0.345
P-value ^d	0.102	0.157	-
Snacks and desserts			
Baseline	41.5 (9.75)	45 (4)	0.171
Day 90	57 (14)	48 (6)	0.021
P-value ^d	0.007	0.096	-

^a Values are expressed as median (IQR) for non-normal distribution.

^b Between-group comparison was applied based on the independent sample *t*-test/Mann-Whitney U test.

^c Non-parametric tests were applied to analyze data.

^d Within-group comparison was applied based on the paired sample *t*-test/Wilcoxon Signed Ranks test.